Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Completed · Phase 4 · NCT04823130
Conditions: Dermatitis Atopic
At a glance
- Research payments reported, 2025
- $20,830
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 54
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (SAR231893) (drug)
- Dates
- Started 2021-04-22; completion 2022-08-30
- Results posted
- Yes
Primary Objective: \- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: * Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus. * To evaluate the efficacy of dupilumab in AD participants with chronic pruritus. * To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.
From ClinicalTrials.gov, last updated 2025-09-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $20,830 in research payments for this study in 2025 (1 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Elias Research Associates LLC $20,830
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.